Loading...
•
Dec 31, 2025
PMV Pharma Q4 2025 Earnings Report
PMV Pharma Q4 2025 Earnings Report
Key Takeaways
PMV Pharma focused on advancing its lead candidate, rezatapopt, through the PYNNACLE clinical trial, achieving Orphan Drug Designation and maintaining a cash runway into 2027. While the company reported a net loss for the fiscal year, it saw a significant reduction in general and administrative expenses due to operational efficiencies.
Enrollment remains on track for the Phase 2 pivotal portion of the PYNNACLE trial for rezatapopt in ovarian cancer.
FDA granted Orphan Drug Designation to rezatapopt for TP53 Y220C positive ovarian cancer in March 2026.
Planned NDA submission for rezatapopt in platinum-resistant/refractory ovarian cancer is set for Q1 2027.
Cash position of $112.9 million provides an expected operational runway through the end of Q2 2027.
Forward Guidance
PMV Pharma expects its current cash reserves to fund operations through the second quarter of 2027, with a major regulatory milestone planned for early 2027.
Positive Outlook
- Cash runway extended to the end of Q2 2027.
- NDA submission for rezatapopt planned for Q1 2027.
- Orphan Drug Designation provides 7 years of market exclusivity if approved.
- Phase 2 enrollment for PYNNACLE trial remains on track.
- Consistent 50% ORR observed in ovarian cancer cohort subgroups.
Challenges Ahead
- Company remains pre-revenue with significant net losses.
- Net cash used in operations increased year-over-year.
- Total liquidity decreased from $183.3 million to $112.9 million.
- Clinical trial success is subject to inherent risks and uncertainties.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...